0.0118 -0.008 (-39.8%) | 04-25 16:00 | |||||||||||||
|
|
Short term | ||||
Mid term | ||||
Targets | 6-month : | 1-year : | ||
Resists | First : | Second : | ||
Pivot price | ||||
Supports | First : | Second : | ||
MAs | MA(5) : | MA(20) : | ||
MA(100) : | MA(250) : | |||
MACD | MACD : | Signal : | ||
%K %D | K(14,3) : | D(3) : | ||
RSI | RSI(14): | |||
52-week | High : | Low : |
If tomorrow: | Open lower | Open higher |
High: | - | - |
Low: | - | - |
Close: | - | - |
Artelo Biosciences, Inc., a clinical stage biopharmaceutical company, focuses on developing and commercializing treatments to modulate the endocannabinoid system. Its product candidate pipeline includes ART27.13, a synthetic dual cannabinoid G protein-coupled receptor agonist, which is in Phase 1b/2a clinical trial for the treatment of anorexia associated with cancer; ART12.11, a synthetic cannabidiol cocrystal for the treatment of inflammatory bowel disease and post-traumatic stress disorder (PTSD); and ART26.12, a fatty acid binding protein 5 inhibitor for treating breast and prostate cancer, neuropathic and nociceptive pain, and anxiety disorders, including PTSD. The company was formerly known as Reactive Medical, Inc. and changed its name to Artelo Biosciences, Inc. in April 2017. Artelo Biosciences, Inc. was incorporated in 2011 and is based in Solana Beach, California.
Tue, 23 Apr 2024
Artelo Biosciences highlights FABP7's role in cancer By Investing.com - Investing.com Nigeria
Mon, 25 Mar 2024
Artelo Biosciences Reports Fiscal 2023 Year-End Financial Results and Provides Business Update - Yahoo Finance
Tue, 12 Mar 2024
Artelo Biosciences Selected as a Finalist in Johnson & Johnson's Innovation Challenge - Yahoo Finance
Thu, 22 Apr 2021
Study explores synthetic cannabinoid for cancer anorexia - OutSourcing-Pharma.com
Fri, 12 Feb 2021
ARTL Stock Alert: The Big Reason Biopharma Artelo Biosciences Is Rocketing Today - Yahoo Finance
Fri, 21 Jun 2019
Artelo Biosciences Announces Pricing of $8.0 Million Public Offering and Uplisting to Nasdaq - GlobeNewswire
Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
Exchange:
NASDAQ
|
|
Sector:
Healthcare
|
|
Industry:
Biotechnology
|
|
Shares Out | 0 (M) |
Shares Float | 0 (M) |
Held by Insiders | (%) |
Held by Institutions | (%) |
Shares Short | 0 (K) |
Shares Short P.Month | 0 (K) |
EPS | |
EPS Est Next Qtrly | |
EPS Est This Year | |
EPS Est Next Year | |
Book Value (p.s.) | |
Profit Margin | % |
Operating Margin | % |
Return on Assets (ttm) | % |
Return on Equity (ttm) | % |
Qtrly Rev. Growth | % |
Gross Profit (p.s.) | |
Sales Per Share | |
EBITDA (p.s.) | |
Qtrly Earnings Growth | % |
Operating Cash Flow | 0 (M) |
Levered Free Cash Flow | 0 (M) |
PE Ratio | |
PEG Ratio | |
Price to Book value | |
Price to Sales | |
Price to Cash Flow |
Dividend | |
Forward Dividend | |
Dividend Yield | 0% |
Dividend Pay Date | |
Ex-Dividend Date |